Analysts Set Novartis AG (VTX:NOVN) PT at CHF 93.38

Shares of Novartis AG (VTX:NOVN) have been given a consensus recommendation of “Hold” by the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is CHF 93.38.

Several research firms recently commented on NOVN. Deutsche Bank set a CHF 92 target price on Novartis and gave the stock a “neutral” rating in a research note on Monday, April 6th. Goldman Sachs Group set a CHF 110 target price on Novartis and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Credit Suisse Group set a CHF 96 target price on Novartis and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. JPMorgan Chase & Co. set a CHF 84 target price on Novartis and gave the stock a “sell” rating in a research note on Friday, May 8th. Finally, Oddo Bhf set a CHF 97 target price on Novartis and gave the stock a “buy” rating in a research note on Monday, June 22nd.

Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Further Reading: How to Invest in Stocks with Increasing Dividends

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.